← Back to patent-cliff list
Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM)
Tier C — Watch / tradeControlled-Ileocolonic-Release Nicotinamide (CICR-NAM)
University Hospitals Of Schleswig-Holstein
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MAPKs
Indications (approved)：Ulcerative colitis
Regional status
US
-
EU
Phase III
2024-09-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM)?
Approved indications include: Ulcerative colitis.
When does the Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) patent expire?
No public expiry year is available for Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) yet; this page updates once verified.
How do I get a quote for Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01